Risk Stratification for Supratherapeutic Peak Anti-Xa Levels in Adult Patients on Therapeutic Enoxaparin.
Shane A SheredyAndrew C StoneAhmad M MostafavifarLisa G MostafavifarRachel M SmithBruce A DoepkerPublished in: The Annals of pharmacotherapy (2023)
, AKI, female sex, ICU service, SOFA score ≥4, and creatinine clearance as risk factors for supratherapeutic anti-Xa levels in patients receiving 1 mg/kg twice daily dosing of enoxaparin. Further research should be done to provide evidence for the association between anti-Xa levels and bleeding risk.